Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories
Analysis
Comment
Deals
Events
News
People

Flotation/IPO

Lemonade demonstrates $319m flotation
SoftBank, XL Catlin, Allianz and Alphabet-backed casualty and property isnurance provider Lemonade priced the initial public offering above its range.
QuantumCTek cultivates $102m IPO
Legend Capital-backed quantum computing technology developer QuantumCTek has filed to raise up to $102m in an initial public offering in Shanghai.
Genor Biopharma generates filing for $320m IPO
The autoimmune disease and cancer drug developer plans to float in Hong Kong having recently secured $160m from investors including a Charoen Pokphand-backed fund.
Berkeley Lights works towards $100m IPO
The cell biology technology provider, which counts Nikon and Varian Medical among its investors, has raised about $215m in venture funding.
Pandion plans $75m initial public offering
SR One and Roche Venture Fund-backed Pandion Therapeutics will use the proceeds from the offering to advance a lead drug candidate for ulcerative colitis.
Akouos acquires $213m in initial public offering
The hearing loss treatment developer, which counts Novartis Venture Fund and Partners Innovation Fund as investors, floated above its range.
Fusion Pharma fetches $213m in IPO
Johnson & Johnson and Varian Medical exited the cancer radiotherapy developer in an upsized initial public offering after $158m in funding.
Agora accomplishes $350m flotation
The SIG-backed video communication software provider priced its shares above the range and will go public later today.

Other News

Relay Therapeutics readies $200m IPO
SoftBank Vision Fund owns more than 40% of the precision cancer drug developer, which raised $400m approximately 18 months ago.
iTeos eyes $100m initial public offering
The 6 Dimensions Capital-backed cancer immunotherapy developer has raised more than $200m in funding and has filed to raise up to $100m.
Forma Therapeutics finishes IPO at $319m
Forma Therapeutics, whose investors include Eli Lilly and Novartis, has closed its IPO after seeing its shares double in price.
Repare rounds off $253m initial public offering
Celgene Switzerland and BMS-backed precision cancer drug developer Repare Therapeutics added $33m to its IPO after its shares rose 65% post-offering.
nCino enters IPO stage
The Salesforce-backed banking platform developer has filed for a $100m initial public offering having raised $80m late last year.
Genetron jumps to public markets in $256m IPO
Vcanbio scored an exit as the precision cancer treatment and diagnostics developer went public in an upsized offering priced well above its range.

Editor's Picks

Lemonade demonstrates $319m flotation
SoftBank, XL Catlin, Allianz and Alphabet-backed casualty and property isnurance provider Lemonade priced the initial public offering above its range.
Forma Therapeutics finishes IPO at $319m
Forma Therapeutics, whose investors include Eli Lilly and Novartis, has closed its IPO after seeing its shares double in price.
Forma forces its way to $278m IPO
The Novartis and Eli Lilly-backed cancer and haematologic disease drug developer will go public today having expanded the size of its offering.
Avidity achieves $259m initial public offering
Muscle disease drug developer Avidity, which counts Eli Lilly, EMS, Takeda and ST Pharm as investors, went public in a significantly upized IPO.
test reg

Login